1 CCA in Ph-negative cells (CCA/PhÀ) are rarely found at CML diagnosis, but can be found in up to 8% of patients receiving imatinib or second generation tyrosine kinase inhibitors (TKIs). Some CCA/PhÀ, especially monosomy 7 or del(7q), predispose to myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) development, whereas others (for example, trisomy 8) are usually transient. 2 There are reports of diploid acute leukemias (AML and ALL (acute lymphoid leukemia)) developing in CML patients receiving imatinib, without CCA/ PhÀ, but with antecedent myelodysplastic features. 3 Rare cases of AML developing in imatinib-treated CML patients with recurrent cytogenetic aberrations in PhÀ cells also exist: one case with t(8;21)(q22;q22) and one case with inv3(q21q26). 4, 5 Clonal hematopoiesis can also be observed in PhÀ cells with different techniques (X-linked human androgen-receptor gene assay and single-nucleotide polymorphism array analysis). 6 We report a CML patient who achieved complete cytogenetic and molecular response receiving imatinib, and then developed AML with normal karyotype and NPM1 ABL1 copies in the samples dated 12, 6 and 3 months before AML diagnosis, respectively (see Figure 1) . The patient had no HLA-matched related donor, and in August 2009 after discontinuation of imatinib, he received induction 2 þ 5 chemotherapy (idarubicin 12 mg/m 2 d1-d2, cytarabine 200 mg/m 2 d1-d5 continuous infusion) and achieved complete remission. He subsequently received 2 þ 5 consolidation therapy (same as above) and two cycles of high-dose cytarabine (HiDAC, 1 g/m 2 d1, d3, d5), remaining off imatinib therapy. In August 2010, the AML [11] . The patient is currently receiving supportive care. Table 1 shows patient's different diseases, molecular aberrations and karyotype over time. Clonal hematopoiesis in PhÀ cells can be found in CML patients receiving TKIs during routine bone marrow cytogenetics or after MDS-related changes have occured (for example, unexplained anemia, neutropenia, thrombocytopenia, dysplastic peripheral-blood smear morphology, increased MCV and so on). Most of these clones do not seem to confer increased risk for progression to AML, whereas other clones (such as monosomy 7 or del(7q)) do. 2 The exact number of CML patients developing AML in PhÀ clones during TKI treatment is not known, but CCA/PhÀ have been described in up to 8% of patients treated with imatinib. 1 The causative role of imatinib in PhÀ MDS/AML development is unknown. In vitro experiments with varying imatinib concentrations on normal human and animal fibroblasts showed that imatinib induced centrosome and chromosome aberrations. 8 In addition, rare cases of MDS and AML have been recorded in gastrointestinal stromal tumor (GIST) patients receiving imatinib, implying a direct effect of TKIs in hematopoiesis. In contrast, CCA/PhÀ have been described in IFN-a-treated CML patients, indicating that some of these aberrations are not triggered by targeted therapy.
9 NPM1 mutation is considered a founder AML genetic lesion, as it resides in the CD34 þ /CD38À leukemic stem cell compartment. NPM1 mutations are found in chemotherapy related AML (t-AML), but in a lower frequency compared with de novo AML. Most of these NPM1 mut t-AML have normal karyotype, indicating a different pathogenesis from t-AML Figure 1 Sequential measurement of NPM1 mut transcript levels before the development of AML. Abbreviations: AML, acute myeloid leukemia; CML, chronic myeloid leukemia.
Letters to the Editor with chromosomal abnormalities, and about half of them carry FLT3-ITD. Chronic phase CML is NPM1 wt , whereas only one case of NPM1 mut myeloid blast crisis CML has been reported.
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IDH1 and IDH2 mutations are also not found in chronic phase CML but can be found at low frequency in blast crisis CML.
11
Here, we present a CML patient who developed clonal hematopoietic disease (AML) in PhÀ cells, with normal karyotype and NPM1 mut , while being in complete CML molecular remission and without previous MDS phase or CCA/PhÀ. The development of PhÀ AML could be the result of inherent genomic instability or a direct effect of TKI therapy, whereas the possibility that AML occurred by chance cannot be excluded. It is should be stressed that sensitive RQ-PCR assay could detect NPM1 mut transcripts 1 year before overt AML, implying that the development of NPM1 mut AML was a slow process. He relapsed twice with clonal evolution: IDH2 R140Q mutation at first relapse and complex karyotype at second relapse. To our knowledge, this is the first report of normal karyotype NPM1 mut AML in PhÀ cells in CML complete remission during imatinib treatment.
Extreme telomere erosion in ATM-mutated and 11q-deleted CLL patients is independent of disease stage Chronic lymphocytic leukaemia (CLL) is considered to arise from a failure of apoptosis and an accumulation of CD5 þ CD23 þ mature B-cells, although significant levels of cell division underlie the clonal growth of these cells. This is apparent from deuterated water incorporation experiments 1 as well as telomere erosion. [2] [3] [4] We have recently shown that the telomere erosion observed in CLL patients is extensive and can result in the loss of telomere function resulting in telomeretelomere fusion events, some of which were clonal; 5 this work also revealed telomeric loss of heterozygosity as well as largescale genomic rearrangements that were concomitant with telomere dysfunction. Telomere dysfunction may therefore account for clonal evolution and the occurrence of large-scale genomic rearrangements, including the loss of 17p and 11q, that confer a poor prognosis and are associated with short telomeres. 3 Short telomeres and telomeric DNA damage are also associated with the development of resistance to DNA damage-induced apoptosis. 6 The telomere dynamics described in CLL are indistinguishable from those observed experimentally in fibroblast cells undergoing a telomere driven 'crisis' in culture following the abrogation of the p53 pathway. 5 In this situation, the loss of cell cycle checkpoints in response to DNA doublestrand breaks (DSBs) facilitates the ongoing cell division beyond the point that would normally trigger telomere-dependent replicative senescence. It is clear from these in vitro studies that there is a subtle distinction between the length of telomere that elicits a cell cycle checkpoint response, triggering p53-dependent replicative senescence or apoptosis and the shorter telomeres that are capable of fusion in cells undergoing 'crisis'. 5 Based on these observations, we hypothesised that in order for CLL cells to achieve substantial telomere erosion and dysfunction they must be compromising in their ability to
